Technical Analysis for BMY - Bristol-Myers Squibb Company

Grade Last Price % Change Price Change
grade A 53.2 0.32% 0.17
BMY closed up 0.32 percent on Monday, October 21, 2019, on 1.37 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Oct 31

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical BMY trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Doji - Bearish? Reversal 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New Uptrend Bullish 0.32%
Upper Bollinger Band Walk Strength 0.32%
Above Upper BB Strength 0.32%

Older signals for BMY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company's products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Chemistry Biopharmaceutical Diabetes Organic Chemistry Schizophrenia Multiple Myeloma Serious Diseases Hypertension Diabetic Nephropathy Treatment Of Diabetes Atrial Fibrillation Bristol Myers Squibb Metastatic Melanoma Stroke Hepatitis C Virus Infection Biopharmaceutical Products Depressive Disorder Chronic Myeloid Leukemia Kidney Transplant Treatment Of Hypertension
Is BMY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 54.81
52 Week Low 42.48
Average Volume 9,592,823
200-Day Moving Average 48.0247
50-Day Moving Average 49.3344
20-Day Moving Average 50.946
10-Day Moving Average 51.713
Average True Range 0.916
ADX 26.58
+DI 33.6864
-DI 13.5806
Chandelier Exit (Long, 3 ATRs ) 50.622
Chandelier Exit (Short, 3 ATRs ) 51.298
Upper Bollinger Band 53.0732
Lower Bollinger Band 48.8188
Percent B (%b) 1.03
BandWidth 8.350803
MACD Line 0.9533
MACD Signal Line 0.7863
MACD Histogram 0.167
Fundamentals Value
Market Cap 87.25 Billion
Num Shares 1.64 Billion
EPS 2.74
Price-to-Earnings (P/E) Ratio 19.42
Price-to-Sales 4.94
Price-to-Book 6.80
PEG Ratio 1.93
Dividend 1.56
Dividend Yield 2.93%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 54.42
Resistance 3 (R3) 54.34 53.85 54.21
Resistance 2 (R2) 53.85 53.54 53.89 54.14
Resistance 1 (R1) 53.53 53.35 53.69 53.61 54.08
Pivot Point 53.04 53.04 53.13 53.08 53.04
Support 1 (S1) 52.72 52.73 52.88 52.80 52.32
Support 2 (S2) 52.23 52.54 52.27 52.26
Support 3 (S3) 51.91 52.23 52.19
Support 4 (S4) 51.99